Bluebird Lenti-D Data Give Gene Therapy Business Another Boost
Results Show Continued Positive Safety, Efficacy Profile
Executive Summary
The news comes less than a week after data partially exonerated its other gene therapy in a cancer scare announced in February.
You may also be interested in...
EU Crunch Time For Bluebird’s Neurodegenerative Disorder Gene Therapy
The EU could become the first market in which eli-cel is approved if the gene therapy for cerebral adrenoleukodystrophy this week passes muster with the European Medicines Agency.
PTC Therapeutics' Gene Therapy Plans Hit By Pandemic
PTC Therapeutics is one of many companies in the life sciences sector whose regulatory targets have been adversely affected by the coronavirus pandemic.
Three Cell And Gene Therapies Reach Critical Review Stage In EU
A number of advanced therapies are likely to be approved in the EU this year.